NASDAQ: INBXV - Inhibrx, Inc.

Rentabilität für sechs Monate: 0%
Dividendenrendite: 0.00%
Sektor: Нефтегаз

Aktionsplan Inhibrx, Inc.

Erweiterter Zeitplan Einfaches Diagramm
Financial Markets by TradingView

Über das Unternehmen Inhibrx, Inc.

Inhibrx, Inc., a clinical-stage biopharmaceutical company, develops a pipeline of novel biologic therapeutic candidates. The company's therapeutic candidate includes INBRX-101, an alpha-1 antitrypsin (AAT)-Fc fusion protein therapeutic candidate, which is in Phase 1 clinical trials for use in the treatment of patients with AAT deficiency.

weitere details
It also develops INBRX-109, a tetravalent therapeutic candidate targeting death receptor 5, which is in Phase 2 clinical trials to treat cancers, such as chondrosarcoma, mesothelioma, colorectal cancer, ewing sarcoma, and pancreatic adenocarcinoma; and INBRX-106, a hexavalent agonist of OX40 for a range of oncology indications. The company has license and collaboration agreements with 2seventy bio, Inc. and Bristol-Myers Squibb Company. Inhibrx, Inc. was incorporated in 2009 and is headquartered in La Jolla, California.
Zur Vergleichsliste hinzufügen
Auf die Beobachtungsliste
Zum Portfolio hinzufügen
Preishinweis hinzufügen

IPO date 2024-05-28
Валюта usd
Сайт https://inhibrx.com
Цена ао 30.85
Preisänderung pro Tag: 0% (30.85)
Preisänderung pro Woche: 0% (30.85)
Preisänderung pro Monat: 0% (30.85)
Preisänderung über 3 Monate: 0% (30.85)
Preisänderung über sechs Monate: 0% (30.85)
Preisänderung seit Jahresbeginn: 0% (30.85)
Alle Parameter

Unterschätzung

Name Bedeutung Grad
P/S 0 0
P/BV 0 0
P/E 0 0
EV/EBITDA 0 0
Gesamt: 2.5

Effizienz

Name Bedeutung Grad
ROA, % 0 0
ROE, % 0 0
Gesamt: 0

Dividenden

Name Bedeutung Grad
Div yield, % 0 0
DSI 0 0
Gesamt: 0

Pflicht

Name Bedeutung Grad
Debt/EBITDA 0 10
Gesamt: 10

Wachstumsimpuls

Name Bedeutung Grad
Rentabilität Revenue, % 0 0
Rentabilität Ebitda, % 0 0
Rentabilität EPS, % 0 0
Gesamt: 0
Weitere Details



Aufsicht Berufsbezeichnung Zahlung Geburtsjahr
Mr. Mark Paul Lappe Founder, Chairman, President & CEO 1967 (58 Jahre)
Dr. Brendan P. Eckelman Ph.D. Founder & Chief Scientific Officer 1979 (46 Jahre)
Mr. Quinn L. Deveraux Founder
Dr. Ashraf Amanullah Executive VP & Chief Technical Operations Officer 1968 (57 Jahre)
Ms. Leah Pollema J.D. VP, Corporate Secretary & General Counsel
Dr. Charbel Helaihel Pharm.D. Vice President of Marketing & Commercial Planning
Mr. Jeffrey J. Jensen Executive VP & Chief Clinical Operations Officer
Mr. David Matly M.B.A. Executive VP and Chief Commercial & Business Development Officer
Dr. Carlos Bais Ph.D. Executive Vice President of Translational Sciences
Dr. Josep Garcia Ph.D. EVP & Chief Clinical Development Officer

Adresse: United States, La Jolla, 11025 North Torrey Pines Road - in Google Maps öffnen, Öffnen Sie Yandex-Karten
Webseite: https://inhibrx.com